Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.

Abstract

Loss of pancreatic islet function and insulin-producing beta cell mass is a central hallmark in the pathogenesis of both type 1 and type 2 diabetes. While in type 1 diabetes this phenomenon is due to an extensive destruction of beta cells caused by an autoimmune process, the mechanisms resulting in beta cell failure in type 2 diabetes are different and less clear. Also, beta cell destruction in type 1 diabetes occurs early and is the initial step in the pathogenetic process, while beta cell loss in type 2 diabetes after an initial phase of hyperinsulinemia due to the underlying insulin resistance occurs relatively late and it is less pronounced. Since diabetes mellitus is the most frequent endocrine disease, with an increasing high prevalence worldwide, huge efforts have been made over the past many decades to identify predisposing genetic, environmental, and nutritional factors in order to develop effective strategies to prevent the disease. In parallel, extensive studies in different cell systems and animal models have helped to elucidate our understanding of the physiologic function of islets and to gain insight into the immunological and non-immunological mechanisms of beta cell destruction and failure. Furthermore, currently emerging concepts of beta cell regeneration (e.g., the restoration of the beta cell pool by regenerative, proliferative and antiapoptotic processes, and recovery of physiologic islet function) apparently is yielding the first promising results. Recent insights into the complex endocrine and paracrine mechanisms regulating the physiologic function of pancreatic islets, as well as beta cell life and death, constitute an essential part of this new and exciting area of diabetology. For example, understanding of the physiological role of glucagon-like peptide 1 has resulted in the successful clinical implementation of incretin-based therapies over the last years. Further, recent data suggesting paracrine effects of growth hormone-releasing hormone and corticotropin-releasing hormone on the regulation of pancreatic islet function, survival, and proliferation as well as on local glucocorticoid metabolism provide evidence for a potential role of the pancreatic islet-stress axis in the pathophysiology of diabetes mellitus. In this chapter, we provide a comprehensive overview of current preventive and regenerative concepts as a basis for the development of novel therapeutic approaches to the treatment of diabetes mellitus. A particular focus is given on the potential of the pancreatic islet-stress axis in the development of novel regenerative strategies.

• Authors: Barbara Ludwig, Andreas Barthel, Andreas Reichel, Norman L Block, Stefan Ludwig, Andrew V Schally, Stefan R Bornstein
• Journal: Vitamins and hormones (Vitam Horm) Vol. 95 Pg. 195-222 ( 2014) ISSN: 0083-6729 [Print] United States
• PMID: 24559919 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)
• Copyright: © 2014 Elsevier Inc. All rights reserved.

Chemical References

• Hypoglycemic Agents
• Insulin

Topics

• Animals
• Diabetes Mellitus, Type 1 (drug therapy, etiology, physiopathology, prevention & control)
• Diabetes Mellitus, Type 2 (drug therapy, etiology, physiopathology, prevention & control)
• Humans
• Hypoglycemic Agents (pharmacology, therapeutic use)
• Insulin (metabolism)
• Insulin Secretion
• Islets of Langerhans (drug effects, metabolism, physiopathology)
• Molecular Targeted Therapy
• Stress, Physiological
• Stress, Psychological (physiopathology)